In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device Business Strategies Innovation

In Devices, KPCB Lands a Big One

Executive Summary

Once viewed as heir apparent for a top job at the merged Guidant/J&J, Dana Mead unexpectedly chose another course and will join venture capital powerhouse Kleiner Perkins as a Partner on its Life Sciences team.

You may also be interested in...



Kleiner Perkins Prepares for Biotech's New Golden Age

Kleiner Perkins, with two new high-profile partners, Beth Seidenberg and Dana Mead, is betting on applied genomics and personalized medicine, making major investments in molecular diagnostics, stem cell therapies, and drug-device convergence.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Table

View full table

Topics

Related Companies

Related Deals

Tags:
Medical Device Business Strategies Innovation
Latest Headlines

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

South Korea Sees Pharma Leadership Transition

FDA-EMA Advice Pilot For Complex Generics: What Does Industry Have To Say?

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

See All
UsernamePublicRestriction

Register

IV002604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By